Successful treatment with sildenafil in systemic sclerosis patients with isolated pulmonary arterial hypertension: two case reports - PubMed (original) (raw)

Case Reports

Successful treatment with sildenafil in systemic sclerosis patients with isolated pulmonary arterial hypertension: two case reports

Ikuko Hayakawa et al. Rheumatol Int. 2006 Jan.

Abstract

We describe two systemic sclerosis (SSc) patients with isolated pulmonary arterial hypertension (PAH) who were given treatment with 50 mg oral sildenafil per day. We evaluated the efficacy of oral sildenafil for isolated PAH in SSc patients by direct assessment with cardiac catheterization before and 6 months after the initiation of sildenafil. Right-heart catheterization demonstrated decreased mean pulmonary artery pressure, decreased pulmonary vascular resistance, and increased cardiac output after treatment with sildenafil. Brain natriuretic peptide levels were gradually decreased. The 6-min walking distance was greatly extended. Moreover, the physical conditions of both patients were much improved. We recognized no adverse events. We propose that oral sildenafil may be beneficial as a selective pulmonary vasodilator and as long-term treatment in SSc patients with isolated PAH.

PubMed Disclaimer

References

1. Curr Opin Rheumatol. 2001 Nov;13(6):495-9 - PubMed
1. Arthritis Rheum. 1986 Apr;29(4):515-24 - PubMed
1. Am J Respir Crit Care Med. 1999 Aug;160(2):600-7 - PubMed
1. Ann Intern Med. 2003 Nov 18;139(10):871-3 - PubMed
1. Circulation. 1999 Jan 5-12;99(1):168-77 - PubMed

Successful treatment with sildenafil in systemic sclerosis patients with isolated pulmonary arterial hypertension: two case reports - PubMed (original) (raw)